Skip to main content

Advertisement

Table 1 Clinical characteristics of patients

From: Endothelial progenitor cells display clonal restriction in multiple myeloma

Case Number Age/Sex Source of EPC %Plasma Cells in BM M protein (g/dL) β2-microglobulin (mg/L) Albumin (mg/mL) Durie/Salmon Stage Cytogenetics
1 53/F PBMC 10 1.2, IgG κ 1.6 2.3 2A ND
2 62/F PBMC 30 1.2, IgG λ 1.8 3.5 2A Normal
3 60/F PBMC 40 2.4, IgG κ 2.2 4.0 2A ND
4 70/F PBMC 80 6.0 IgG κ 3.0 3.5 3A ND
5 54/F PBMC 15 1.1, IgG κ 6.8 2.4 2A ND
6 55/F BM 10 3.0, IgG κ 2.0 3.4 2A Normal
7 50/F PBMC 30 4.8, IgG κ 4.6 3.7 3A ND
8 46/F PBMC 10 2.8, κ LC 4.9 3.9 3A ND
9 52/F BM 5 1.1, IgG κ 2.6 4.0 1A ND
10 56/F PBMC 30 2.0, λ LC 1.4 4.2 3A ND
11 73/F BM 10 3.0, IgG κ 2.4 3.8 1A Normal
12 66/M BM 10 3.0, IgG κ 2.0 4.1 1A ND
13 56/F BM 95 7.0, IgG κ 3.7 3.2 3A Normal
14 54/F BM 90 2.9, IgG λ 1.8 4.0 2A ND
15 53/M BM 95 3.6, IgA κ 3.0 3.0 3A Normal
16 66/F BM 60 5.4, IgA λ 3.5 1.9 3A Normal
  1. Percent of plasma cells in BM indicates extent of myeloma involvement determined by histochemistry in the BM biopsies
  2. Normal cytogenetics indicates results of chromosome banding studies and FISH performed using DNA probe D13S319 (Vysis Inc., Vysis, IL) for detection of 13q14.2 deletion
  3. This patient had antecedent MGUS
  4. "PBMC" peripheral blood mononuclear cells; "BM" bone marrow; "ND" Not done